Amendments to the Specification:

Please amend the specification as shown:

Please delete paragraph [0009] on pages 5 and 6, and replace it with the following paragraph:

[0009] In one embodiment of the present invention, the Class III anti-CEA monoclonal antibody or fragment thereof is preferably a MN-14 antibody or fragment thereof. More preferably, the MN-14 monoclonal antibody or fragment thereof comprises the complementarity-determining regions (CDRs) of a murine MN-14 monoclonal antibody, wherein the CDRs of the light chain variable region of the MN-14 antibody comprises CDR1 comprising the amino acid sequence KASQDVGTSVA **(SEQ ID NO: 20)**; CDR2 comprising the amino acid sequence WTSTRHT **(SEQ ID NO: 21)**; and CDR3 comprising the amino acid sequence QQYSLYRS **(SEQ ID NO: 22)**; and the CDRs of the heavy chain variable region of the Class III anti-CEA antibody comprises CDR1 comprising TYWMS **(SEQ ID NO: 23)**; CDR2 comprising EIHPDSSTINYAPSLKD **(SEQ ID NO: 24)**; and CDR3 comprising LYFGFPWFAY **(SEQ ID NO: 25)**. Also preferred, the MN-14 monoclonal antibody reacts with CEA and is unreactive with normal cross-reactive antigen (NCA) and meconium antigen (MA). Most preferably, the MN-14 monoclonal antibody or fragment thereof is a humanized, chimerized or fully human MN-14 antibody or fragment thereof.

Please delete paragraph [0013] on page 7, and replace it with the following paragraph:

[0013] In a preferred embodiment, the Class III anti-CEA monoclonal antibody or fragment thereof is a MN-14 antibody or fragment thereof. Preferably, the MN-14 monoclonal antibody or fragment thereof comprises the complementarity-determining regions (CDRs) of a murine MN-14 monoclonal antibody, wherein the CDRs of the light chain variable region of said MN-14 antibody comprises CDR1 comprising the amino acid sequence KASQDVGTSVA **(SEQ ID NO: 20)**; CDR2 comprising the amino acid sequence WTSTRHT **(SEQ ID NO: 21)**; and CDR3 comprising the amino acid sequence QQYSLYRS **(SEQ ID NO: 22)**; and the CDRs of the heavy chain variable region of said Class III anti-CEA antibody comprises CDR1 comprising TYWMS **(SEQ ID NO: 23)**; CDR2 comprising EIHPDSSTINYAPSLKD **(SEQ ID NO: 24)**; and CDR3 comprising LYFGFPWFAY **(SEQ ID NO: 25)**. Also preferred, the MN-14 monoclonal antibody is humanized, chimerized or fully human, and reacts with CEA and is unreactive with normal cross-reactive antigen (NCA) and meconium antigen. Also preferred, the MN-14 antibody or fragment thereof is administered in a dosage of 100 to 600 milligrams protein per dose per injection. Most preferably, the MN-14 antibody or fragment thereof is administered in a dosage of 300-400 milligrams protein per dose per injection.

Please amend paragraph 25 on page 10 as follows:

[0025] **Figure 3.** Graph comparing the therapeutic efficacy of several chemotherapeutic drugs on tumor volume in TT bearing mice. **TT bearing mice were given doxorubicin @ 20 mg/m^2; days 0, 1, and 2, (70 μg/dose) (O); DTIC @ 300 mg/m^2; days 0, 1, and 2, (1.08 mg/dose) (□); doxorubicin and DTIC as above (•); cyclophosphamide @ 600 mg/m^2; day 0 (2.16 mg/dose) (Δ); vincristine @ 4.2 μg/dose; day 0 (x); all 4 drugs (doxorubicin, DTIC, cyclophosphamide, and vincristine, at the doses described for each above (■); or left untreated (♦). Groups consisted of 6-9 nude mice bearing established TT tumors. Mean tumor volume at time of treatment was 0.51 +/- 0.33 cm^3. Points: mean tumor size. Error bars: std dev, and are shown only above the symbol for clarity.**

Please amend paragraph 26 on page 10 as follows:

[0026] **Figure 4.** Graph comparing the therapeutic efficacy of combination therapy of RAIT with ^{90}Y-labeled anti CEA MAb MN-14 and a 4-drug combination initiated 24 hours after RAIT on tumor volume in mice. **Tumor bearing animals were either left untreated (♦); given the 4-drug regimen described in Fig 1, administered on days 1, 2, and 3 (■); 52.5 μCi ^{90}Y-MN-14 day on 0, followed by the 4-drug regimen administered on days 1, 2, and 3 (▲); 52.5 μCi ^{90}Y-MN-14 on day 0 (Δ); or 105 μCi ^{90}Y-MN-14 on day 0 (O). N=5 for the untreated group, and n=9-10 in the treatment groups. Mean tumor volume at time of treatment was 0.28 +/- 0.12 cm^3. Points: mean tumor size. Error bars: std dev, and are shown only above the symbol for clarity.**

Please amend paragraph 27 on page 10 as follows:

[0027] **Figure 5.** Graph comparing the efficacy of RAIT plus DTIC and RAIT plus doxorubicin and DTIC in TT bearing mice. **TT bearing mice were either left untreated (♦); given 105 µCi ^{90}Y-MN-14 day on 0 (O); 105 µCi ^{90}Y-MN-14 day on 0, followed by the doxorubicin and DTIC regimen administered at 50% the full dosage on days 1, 2, and 3 (▲); 105 µCi ^{90}Y-MN-14 day on 0 followed by DTIC at 75% of the full dosage on days 1, 2, and 3 (x); or the full dosage of DTIC, 300 mg/m^2 on days 1, 2, and 3, (1.08 mg/dose) (□). N=5 for the untreated group, and n=8-9 in the treatment groups. Mean tumor volume at time of treatment was 0.39 +/- 0.20 cm^3. Points: mean tumor size. Error bars: std dev, and are shown only above the symbol for clarity.**

Please amend paragraph 28 on page 10 as follows:

[0028] **Figure 6.** Graph comparing **the** effectiveness of naked hMN-14 **with** treatment regimens in mice bearing TT xenografts **[[with]]**. Animals were given s.c. injections of TT cells, and either left untreated (A) or given an i.v. injection of 0.5 mg hMN-14 1 day (B) or 11 days (C) later. **Lines in panels A, B, and C represent tumor volumes of individual animals. Means of respective treatment groups are shown in panel D. Error bars represent standard error of the mean and are shown only in one direction for clarity. ♦, untreated; □, day-1 treated; Δ, day-11 treated.**

Please amend paragraph 29 on page 11 as follows:

[0029] **Figure 7.** Graph comparing the effectiveness of humanized and murine MN-14 antibodies in treating medullary thyroid carcinoma. Animals were given s.c. injections of TT cells, and either left untreated or given an i.v. injection of M[[a]]Ab (0.5 mg) 1 day later. **Means of respective treatment groups are shown. Error bars represent standard error of the mean and are shown only in one direction for clarity. ♦, untreated; □, hMN-14; Δ, murine MN-14; x, hLL2.**

Please amend paragraph 30 on page 11 as follows:

[0030] **Figure 8.** Graph comparing the effectiveness of different hMN-14 doses in treating medullary thyroid carcinoma. Animals were given i.v. of increasing doses of hMN-14 1 day after s.c. injection of TT cells. **Means of respective treatment groups are shown. ◆, untreated; •, 0.125 mg; O, 0.25 mg; ■, 0.50 mg; x, 1.0 mg, ▲, 2.0 mg. Error bars represent standard error of the mean and are shown only for the untreated group and the group that received 0.50 mg hMN-14/mouse for clarity.**

Please amend paragraph 31 on page 11 as follows:

[0031] **Figure 9.** Graph comparing the effectiveness of different treatment times in TT bearing nude mice. **Animals were given i.v. injections of 0.25 hMN-14 either 1 (•), 3 (▲), or 7 (■) days after s.c. injection of TT cells, or left untreated (◆). Means of respective treatment groups are shown. Error bars represent standard error of the mean and are shown only in one direction for clarity.**

Please amend paragraph 32 on page 11 as follows:

[0032] Figure 10. Graph comparing treatment of TT bearing nude mice with hMN-14 plus DTIC, DTIC, alone, hMN-14 alone, and untreated mice. Animals were given i.p. injections of hMN-14 at 100 μg/dose on days 2, 3, 4, 5, 7, 8, 9, 10 and 11, 15, and 22, then every 7 days (O); DTIC, 75 μg/dose on days 2, 3, and 4, (▲); the combination of these hMN-14 and DTIC regimens (Δ); or left untreated (◆). Means of respective treatment groups are shown. 10 animals/group.

Please delete paragraph [0033] on page 11, and replace it with the following paragraph:

[0033] **Figure 11.** Figures 11A and 11 B show the consensus DNA sequence of the murine MN-14 variable region heavy chain (VH) **(SEQ ID NO: 1)** and the amino acid sequence **(SEQ ID NO: 2)** encoded by the DNA sequence. The CDRs are enclosed in boxes.

Please delete paragraph [0034] on page 11, and replace it with the following paragraph:

[0034] **Figure 12.** Figures 12A and 12 B show the consensus DNA sequence of the murine MN-14 variable region light chain (VK) **(SEQ ID NO: 3)** and the amino acid sequence **(SEQ ID NO: 4)** encoded by the DNA sequence. The CDRs are enclosed in boxes.

Please delete paragraph [0035] on page 11, and replace it with the following paragraph:

[0035] **Figure 13.** Figures 13A and 13B show the alignment of the murine MN-14 variable region **(MN14VH is shown in SEQ ID NO: 2, MN14VK is shown in SEQ ID NO: 4)** of the with the human variable regions NEWM VH **(SEQ ID NO: 5)** and REI VK **(SEQ ID NO: 6)** (Figure 13A). and with the human KOL VH region **(SEQ ID NO: 7)** (Figure 13B). CDRs are boxed, and the murine VH FRs, which are incorporated into the humanized VH, are marked with their positions according to the numbering system of Kabat et al. SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST, U.S. Government Printing Office, Washington, D.C., 1987. Murine residues outside the CDRs that were included in the KLHuVH are indicated by a filled circle.

Please delete paragraph [0036] on pages 11 and 12, and replace it with the following paragraph:

[0036] **Figure 14.** Figures 14A-14C show a comparison of the amino acid sequence between murine and humanized MN-14 VH framework residues (FR) **(SEQ ID NOS 2, 26, 8-11, 27 and 12-15, respectively in order of appearance)**. Only human FR residues different from the mouse are shown. CDRs for NEWM and KOL are also not shown. The areas of amino acid substitutions in the respective FRs are highlighted in bold, and the position of the substitution indicated according to the Kabat et al. numbering system. The 3 CDRs are boxed.

Please delete paragraph [0044] on page 12, and replace it with the following paragraph:

[0044] **Figure 22.** Figures 22A and 22B show the comparison of the human, murine and humanized sequences of the Vk and VH regions of the human REI and KOL antibodies, respectively with murine and humanized MN-14. The human sequences of the REI Vk **(SEQ ID NO: 6)** in Figure 22A are compared with the murine **(SEQ ID NO: 4)** and humanized **(SEQ ID NO: 19)** MN-14 Vk sequences. The closed circles indicate sequences retained from the humanREI Vk sequences. The CDRs are boxed. The human sequences of the KOL VH **(SEQ ID NO: 7)** in Figure 22B are compared with the murine **(SEQ ID NO: 2)** and humanized **(SEQ ID NO: 14)** MN-14 VH sequences. The closed circles indicate sequences retained from the human KOL VH sequences. The CDRs are boxed.

Please delete paragraph [0045] on page 13, and replace it with the following paragraph:

[0045] **Figure 23.** Figures 23A and 23B show the Vk, the variable light chain, and the VH, the variable heavy chain sequences of hMN-14, a humanized Class III anti-CEA antibody. The CDR region sequences are shown in bold and underlined. The amino acid residues and the nucleotides are numbered sequentially. The light chain variable region is shown in Fig. 23A **(Nucleotide and encoded protein are disclosed as SEQ ID NOS 18 and 19, respectively)** and the heavy chain variable region is shown in Fig. 23B **(Nucleotide and encoded protein are disclosed as SEQ ID NOS 16 and 17, respectively).**

Please delete paragraph [0091] on page 29, and replace it with the following paragraph:

[0091] In a preferred embodiment, the Class III anti-CEA monoclonal antibody or fragment thereof is a MN-14 antibody or fragment thereof. Preferably, the MN-14 monoclonal antibody or fragment thereof comprises the complementarity-determining regions (CDRs) of a murine MN-14 monoclonal antibody, wherein the CDRs of the light chain variable region of said MN-14 antibody comprises CDR1 comprising the amino acid sequence KASQDVGTSVA **(SEQ ID NO: 20)**; CDR2 comprising the amino acid sequence WTSTRHT **(SEQ ID NO: 21)**; and CDR3 comprising the amino acid sequence QQYSLYRS **(SEQ ID NO: 22)**; and the CDRs of the heavy chain variable region of said Class III anti-CEA antibody comprises CDR1 comprising TYWMS **(SEQ ID NO: 23)**; CDR2 comprising EIHPDSSTINYAPSLKD **(SEQ ID NO: 24)**; and CDR3 comprising LYFGFPWFAY **(SEQ ID NO: 25)**. Also preferred, the MN-14 monoclonal antibody reacts with CEA and is unreactive with normal cross-reactive antigen (NCA) and meconium antigen (MA). However, antibodies against these cross-reactive determinants may be used in combination therapy with CEA-specific antibodies, such as combined with the MN-14 monoclonal antibody.

Please delete paragraph [0122] on page 43, and replace it with the following paragraph:

[0122] 6. The composition of embodiment 5, wherein said MN-14 monoclonal antibody or fragment thereof comprises the complementarity-determining regions (CDRs) of a murine MN-14 monoclonal antibody, wherein the CDRs of the light chain variable region of said MN-14 antibody comprises CDR1 comprising the amino acid sequence KASQDVGTSVA **(SEQ ID NO: 20)**; CDR2 comprising the amino acid sequence WTSTRHT **(SEQ ID NO: 21)**; and CDR3 comprising the amino acid sequence QQYSLYRS **(SEQ ID NO: 22)**; and the CDRs of the heavy chain variable region of said anti-CEA antibody comprises CDR1 comprising TYWMS **(SEQ ID NO: 23)**; CDR2 comprising EIHPDSSTINYAPSLKD **(SEQ ID NO: 24)**; and CDR3 comprising LYFGFPWFAY **(SEQ ID NO: 25)**.

Please delete paragraph [0143] on page 46, and replace it with the following paragraph:

[0143] 27. The method of embodiment 23, wherein said MN-14 monoclonal antibody or fragment thereof comprises the complementarity-determining regions (CDRs) of a murine MN-14 monoclonal antibody, wherein the CDRs of the light chain variable region of said MN-14 antibody comprises CDR1 comprising the amino acid sequence KASQDVGTSVA **(SEQ ID NO: 20)**; CDR2 comprising the amino acid sequence WTSTRHT **(SEQ ID NO: 21)**; and CDR3 comprising the amino acid sequence QQYSLYRS **(SEQ ID NO: 22)**; and the CDRs of the heavy chain variable region of said anti-CEA antibody comprises CDR1 comprising TYWMS **(SEQ ID NO: 23)**; CDR2 comprising EIHPDSSTINYAPSLKD **(SEQ ID NO: 24)**; and CDR3 comprising LYFGFPWFAY **(SEQ ID NO: 25)**.

Please delete paragraph [0176] on pages 50 and 51, and replace it with the following paragraph:

[0176] 60. The method of embodiment 59, wherein said MN-14 monoclonal antibody or fragment thereof comprises the complementarity-determining regions (CDRs) of a murine MN-14 monoclonal antibody, wherein the CDRs of the light chain variable region of said MN-14 antibody comprises CDR1 comprising the amino acid sequence KASQDVGTSVA **(SEQ ID NO: 20)**; CDR2 comprising the amino acid sequence WTSTRHT **(SEQ ID NO: 21)**; and CDR3 comprising the amino acid sequence QQYSLYRS **(SEQ ID NO: 22)**; and the CDRs of the heavy chain variable region of said Class III anti-CEA antibody comprises CDR1 comprising TYWMS **(SEQ ID NO: 23)**; CDR2 comprising EIHPDSSTINYAPSLKD **(SEQ ID NO: 24)**; and CDR3 comprising LYFGFPWFAY **(SEQ ID NO: 25)**.